NITINOL MEDICAL TECHNOLOGIES INC
S-8, 1998-11-13
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Previous: LIGHTBRIDGE INC, 10-Q, 1998-11-13
Next: NITINOL MEDICAL TECHNOLOGIES INC, 10-Q, 1998-11-13



<PAGE>
 
              As filed with the Securities and Exchange Commission
                              on November 13, 1998
                                                      Registration No. 333-_____
================================================================================

                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                   FORM S-8

                         REGISTRATION STATEMENT UNDER
                          THE SECURITIES ACT OF 1933

                      NITINOL MEDICAL TECHNOLOGIES, INC.
            (Exact name of registrant as specified in its charter)

           DELAWARE                                      95-4090463
(State or other jurisdiction of                       (I.R.S. Employer
 incorporation or organization)                     Identification Number)


27 WORMWOOD STREET, BOSTON MASSACHUSETTS                    02210
(Address of Principal Executive Offices)                 (Zip Code)


                           1998 STOCK INCENTIVE PLAN
                            (Full title of the Plan)

                                THOMAS M. TULLY
                            CHIEF EXECUTIVE OFFICER
                       NITINOL MEDICAL TECHNOLOGIES, INC.
                               27 WORMWOOD STREET
                          BOSTON, MASSACHUSETTS 02210

                                WITH A COPY TO:
                                STEVEN D. SINGER
                               HALE AND DORR LLP
                                60 STATE STREET
                                BOSTON, MA 02109

           (Name, address, including zip code, and telephone number,
                  including area code, of agent for service)

================================================================================

                        CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
                                                     Proposed
Title of                            Proposed         maximum      
securities         Amount           maximum          aggregate       Amount of
to be              to be            offering price   offering        registration
registered         registered       per share        price           fee
- --------------     -------------    --------------   -------------   ------------
<S>                <C>             <C>              <C>            <C>
Common Stock,      800,000 shares      $4.72(1)       $3,776,000(1)     $1,050
$.001 par value
</TABLE>
(1) Estimated solely for the purpose of calculating the registration fee, and
    based upon the average of the high and low prices of the Common Stock on the
    Nasdaq National Market on  November 12, 1998 in accordance with Rules 457(c)
    and 457(h) of the Securities Act of 1933.

===============================================================================
<PAGE>
 
PART I.  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

       The information required by Part I is included in documents sent or given
to participants in the Registrant's 1998 Stock Incentive Plan pursuant to Rule
428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act").


PART II.  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     Item 3.  Incorporation of Certain Documents by Reference
              -----------------------------------------------

       The following documents, which are filed with the Securities and Exchange
Commission (the "Commission"), are incorporated in this Registration Statement
by reference:

       (1) The Registrant's latest annual report filed pursuant to Sections
     13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the
     "Exchange Act"), or the latest prospectus filed pursuant to Rule 424(b)
     under the Securities Act that contains audited financial statements for the
     registrant's latest fiscal year for which such statements have been filed.

       (2) All other reports filed pursuant to Sections 13(a) or 15(d) of the
     Exchange Act since the end of the fiscal year covered by the annual report
     or the prospectus referred to in (1) above.

       (3) The description of the common stock of the Registrant, $.001 par
     value per share (the "Common Stock"), contained in the Registrant's
     Registration Statement on Form 8-A filed under the Exchange Act, including
     any amendment or report filed for the purpose of updating such description.

       All documents subsequently filed by the Registrant pursuant to Sections
13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-
effective amendment which indicates that all shares of Common Stock offered
hereby have been sold or which deregisters all shares of Common Stock then
remaining unsold, shall be deemed to be incorporated by reference herein and to
be part hereof from the date of the filing of such documents.  Any statement
contained in a document incorporated or deemed to be incorporated by reference
herein shall be deemed to be modified or superseded for purposes of this
Registration Statement to the extent that a statement contained herein or in any
other subsequently filed document which also is or is deemed to be incorporated
by reference herein modifies or supersedes such statement.  Any statement so
modified or superseded shall be deemed, except as so modified or superseded, to
constitute a part of this Registration Statement.

     Item 4.  Description of Securities
              -------------------------

       Not applicable.

     Item 5.  Interests of Named Experts and Counsel
              --------------------------------------

       Not Applicable.

     Item 6.  Indemnification of Directors and Officers
              -----------------------------------------

       Section 145 of the General Corporation Law of Delaware provides that a
corporation has the power to indemnify a director, officer, employee or agent of
the corporation and certain other

                                      -1-
<PAGE>
 
persons serving at the request of the corporation in related capacities against
amounts paid and expenses incurred in connection with an action or proceeding to
which he is or is threatened to be made a party by reason of such position, if
such person shall have acted in good faith and in a manner he reasonably
believed to be in or not opposed to the best interests of the corporation, and,
in any criminal proceeding, if such person had no reasonable cause to believe
his conduct was unlawful; provided that, in the case of actions brought by or in
the right of the corporation, no indemnification shall be made with respect to
any matter as to which such person shall have been adjudged to be liable to the
corporation unless and only to the extent that the adjudicating court determines
that such indemnification is proper under the circumstances.

     Article EIGHTH of the Registrant's Second Amended and Restated Certificate
of Incorporation provides that a director, officer, employee, or agent of the
Registrant shall be indemnified by the Registrant to the fullest extent
authorized by the General Corporation Law of Delaware, against all expense,
liability, and loss (including attorneys' fees, judgments, fines, excise or
other taxes assessed with respect to an employee benefit plan, penalties, and
amounts paid in settlement) reasonably incurred or suffered by him in connection
with any litigation or other legal proceeding brought against him by virtue of
his position as a director, officer, employee or agent of the Registrant.
Expenses incurred in defending an action, suit or proceeding shall be advanced
by the Registrant to a director or officer, at his request, upon receipt of an
undertaking by the director or officer to repay such amount if it is ultimately
determined that he is not entitled to indemnification.

     Indemnification is required to be made unless the Registrant determines
that the applicable standard of conduct required for indemnification has not
been met.  If the Registrant fails to make an indemnification payment within 60
days after such payment is claimed by such person, or, in the case of a claim
for an advancement of expenses, within 20 days after such payment is claimed,
such person may bring suit against the Registrant to recover the unpaid amount
of the claim.  If successful in whole or in part in any such suit, or in a suit
brought by the Registrant to recover an advancement of expenses pursuant to the
terms of an undertaking, such person shall also be entitled to be paid the
expense of prosecuting or defending such suit.

     Article Eighth of the Registrant's Second Amended and Restated Certificate
of Incorporation further provides that the indemnification provided therein is
not exclusive, and provides that in the event the General Corporation Law of
Delaware is amended to expand the indemnification permitted to directors,
officers, employees and agents, the Registrant must indemnify those persons to
the fullest extent permitted by such law as so amended.

     Article EIGHTH of the Registrant's Second Amended and Restated Certificate
of Incorporation provides that the Registrant may maintain insurance, at its
expense, to protect itself and any director, officer, employee, or agent of the
Registrant or another corporation, partnership, joint venture, trust, or other
enterprise against any expense, liability, or loss, whether or not the
Registrant would have the power to indemnify such person against such expense,
liability, or loss under the General Corporation Law of Delaware.

     Article NINTH of the Registrant's Second Amended and Restated Certificate
of Incorporation provides that, except to the extent that the General
Corporation Law of Delaware prohibits the elimination or limitation of liability
of directors for breaches of fiduciary duty, no director of the Registrant shall
be personally liable to the Registrant or its stockholders for monetary damages
for any breach of fiduciary duty as a director.

     Item 7.  Exemption from Registration Claimed
              -----------------------------------
 
              Not applicable.

                                      -2-
<PAGE>
 
     Item 8.    Exhibits
                --------
Exhibit
Number          Description
- ----------      -----------
4.1 (1)         Second Amended and Restated Certificate of Incorporation

4.2 (2)         Amended and Restated By-Laws of the Registrant

4.3 (2)         Specimen certificate for shares of common stock

5.1             Opinion of Hale and Dorr LLP

23.1            Consent of Arthur Andersen LLP

23.2            Consent of Hale and Dorr LLP (included in Exhibit 5.1)

24              Power of Attorney (included on the signature page
                to this Registration Statement)

______
(1)  Incorporated herein by reference to Exhibit 3.1 from the Registrant's 
     Quarterly Report on Form 10-Q for the quarter ended June 30, 1998 
     (File No. 000-21001), filed with the Commission on August 5, 1998.

(2)  Incorporated herein by reference from the Registrant's Registration
     Statement on Form S-1 (File No. 33-06463), filed with the Commission on
     June 20, 1996.

     Item 9.  Undertakings
              ------------

     1.  The Registrant hereby undertakes:

       (1) To file, during any period in which offers or sales are being made, a
     post-effective amendment to this Registration Statement:

           (i) To include any prospectus required by Section 10(a)(3) of the
          Securities Act;

           (ii) To reflect in the prospectus any facts or events arising after
          the effective date of the Registration Statement (or the most recent
          post-effective amendment thereof) which, individually or in the
          aggregate, represent a fundamental change in the information set forth
          in the Registration Statement; and

          (iii) To include any material information with respect to the plan
          of distribution not previously disclosed in the Registration Statement
          or any material change to such information in the Registration
          Statement;

     PROVIDED, HOWEVER, that paragraphs (i) and (ii) do not apply if the
information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed with or furnished to the
Commission by the Registrant pursuant to Section 13 or Section 15(d) of the
Exchange Act that are incorporated by reference in the Registration Statement.

       (2) That, for the purpose of determining any liability under the
     Securities Act, each such post-effective amendment shall be deemed to be a
     new Registration Statement relating to the

                                      -3-
<PAGE>
 
     securities offered therein, and the offering of such securities at that 
     time shall be deemed to be the initial bona fide offering thereof.

       (3) To remove from registration by means of a post-effective amendment
     any of the securities being registered which remain unsold at the
     termination of the offering.

     2.  The Registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act, each filing of the Registrant's annual
report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is
incorporated by reference in the Registration Statement shall be deemed to be a
new Registration Statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.

     3.  Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the foregoing provisions, or otherwise, the Registrant
has been advised that in the opinion of the Commission such indemnification is
against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the Registrant of expenses incurred or
paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.

                                      -4-
<PAGE>
 
                                   SIGNATURES

     Pursuant to the requirements of the Securities Act, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Boston, Commonwealth of Massachusetts, on this 
12th day of November, 1998.

                                      NITINOL MEDICAL TECHNOLOGIES, INC.



                                      By: /s/ Thomas M. Tully
                                          -------------------------------
                                          Thomas M. Tully
                                          Chief Executive Officer and President


                               POWER OF ATTORNEY

  We, the undersigned officers and directors of Nitinol Medical Technologies,
Inc., hereby severally constitute and appoint Thomas M. Tully and Steven D.
Singer, and each of them singly, our true and lawful attorneys with full power
to any of them, and to each of them singly, to sign for us and in our names in
the capacities indicated below the Registration Statement on Form S-8 filed
herewith and any and all pre-effective and post-effective amendments to said
Registration Statement and generally to do all such things in our name and
behalf in our capacities as officers and directors to enable Nitinol Medical
Technologies, Inc. to comply with the provisions of the Securities Act and all
requirements of the Securities and Exchange Commission, hereby ratifying and
confirming our signatures as they may be signed by our said attorneys, or any of
them, to said Registration Statement and any and all amendments thereto.

  Pursuant to the requirements of the Securities Act of 1933, this Registration
Statement has been signed by the following persons in the capacities and on the
date indicated.

<TABLE> 
<CAPTION> 
           Signature                                  Title                             Date
- -------------------------------  -----------------------------------------------  -----------------
<S>                              <C>                                              <C> 
/s/ Thomas M. Tully              Chief Executive Officer, President and           November 12, 1998
- -------------------------------  Director
   Thomas M. Tully               (Principal Executive Officer)
 
 
/s/ William J. Knight            Chief Financial Officer and Vice President of    November 12, 1998
- -------------------------------  Finance and Administration
   William J. Knight             (Principal Financial Officer)
 
/s/ Morris Simon                 Director                                         November 12, 1998
- ------------------------------- 
   Morris Simon, M.D.

/s/ C. Leonard Gordon            Director                                         November 12, 1998
- ------------------------------- 
   C. Leonard Gordon
                               
/s/ Michael C. Brooks            Director                                         November 12, 1998
- ------------------------------- 
   Michael C. Brooks
   
/s/ R. John Fletcher             Director                                         November 12, 1998
- ------------------------------- 
   R. John Fletcher
                               
/s/ Jeffrey R. Jay               Director                                         November 12, 1998
- ------------------------------- 
   Jeffrey R. Jay, M.D.
                               
 /s/ Robert A. Van Tassel        Director                                         November 12, 1998
- -------------------------------
   Robert A. Van Tassel, M.D.
</TABLE> 

                                      -5-
<PAGE>
 
                                 EXHIBIT INDEX
                                 -------------


Exhibit
Number     Description
- -------    -----------
4.1 (1)    Second Amended and Restated Certificate of Incorporation
4.2 (2)    Amended and Restated By-Laws of the Registrant
4.3 (2)    Specimen certificate for shares of common stock
5.1        Opinion of Hale and Dorr LLP
23.1       Consent of Arthur Andersen LLP
23.2       Consent of Hale and Dorr LLP (included in Exhibit 5.1)
24         Power of Attorney (included on the signature page
           to this Registration Statement)

______
(1)  Incorporated herein by reference to Exhibit 3.1 from the Registrant's 
     Quarterly Report on Form 10-Q for the quarter ended June 30, 1998 
     (File No. 000-21001), filed with the Commission on August 5, 1998.

(2)  Incorporated herein by reference from the Registrant's Registration 
     Statement on Form S-1 (File No. 33-06463), filed with the Commission
     on June 20, 1996.

<PAGE>
 
                                                                     EXHIBIT 5.1

                               HALE AND DORR LLP
                               COUNSELLORS AT LAW

                 60 STATE STREET, BOSTON, MASSACHUSETTS  02109
                        617-526-6000 . FAX 617-526-5000


                              November 13, 1998


Nitinol Medical Technologies, Inc.
27 Wormwood Streeet
Boston, MA 02210

     Re:  1998 Stock Incentive Plan

Ladies and Gentlemen:

     This opinion is furnished to you in connection with a Registration
Statement on Form S-8 (the "Registration Statement") to be filed with the
Securities and Exchange Commission (the "Commission") under the Securities Act
of 1933, as amended (the "Securities Act"), for the registration of 800,000
shares of Common Stock, $.001 par value per share (the "Shares"), of Nitinol
Medical Technologies, Inc., a Delaware corporation (the "Company"), issuable
under the Company's 1998 Stock Incentive Plan (the "Plan").

     We have examined the Second Amended and Restated Certificate of
Incorporation and the Amended and Restated By-laws of the Company and originals,
or copies certified to our satisfaction, of all pertinent records of the
meetings of the directors and stockholders of the Company, the Registration
Statement and such other documents relating to the Company as we have deemed
material for the purposes of this opinion.

     In our examination of the foregoing documents, we have assumed the
genuineness of all signatures and the authenticity of all documents submitted to
us as originals, the conformity to original documents of all documents submitted
to us as copies, the authenticity of the originals of such latter documents and
the legal competence of all signatories to such documents.

     We express no opinion herein as to the laws of any state or jurisdiction
other than the state laws of the Commonwealth of Massachusetts, the Delaware
General Corporation Law statute and the federal laws of the United States of
America.

     Based upon and subject to the foregoing, we are of the opinion that the
Company has duly authorized for issuance the Shares, and the Shares, when issued
and paid for in accordance with the terms of the Plan and at a price per share
in excess of the par value per share for such Shares, will be validly issued,
fully-paid and nonassessable.


WASHINGTON, D.C.                 BOSTON, MA                         LONDON, UK*
- --------------------------------------------------------------------------------
             HALE AND DORR LLP INCLUDES PROFESSIONAL CORPORATIONS
 *BROBECK HALE AND DORR INTERNATIONAL (AN INDEPENDENT JOINT VENTURE LAW FIRM)
<PAGE>
 
Nitinol Medical Technologies, Inc.
November 13, 1998
Page 2



     It is understood that this opinion is to be used only in connection with
the offer and sale of the Shares while the Registration Statement is in effect.

     This opinion is based upon currently existing statutes, rules, regulations
and judicial decisions, and we disclaim any obligation to advise you of any
change in any of these sources of law or subsequent legal or factual
developments which might affect any matters or opinions set forth herein.

     Please note that we are opining only as to the matters expressly set forth
herein, and no opinion should be inferred as to any other matters.

     We hereby consent to the filing of this opinion with the Commission as an
exhibit to the Registration Statement in accordance with the requirements of
Item 601(b)(5) of Regulation S-K under the Securities Act.  In giving such
consent, we do not hereby admit that we are in the category of persons whose
consent is required under Section 7 of the Securities Act or the rules and
regulations of the Commission.

                                                Very truly yours,



                                                HALE AND DORR LLP

<PAGE>
 
                                                                    EXHIBIT 23.1


                   CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

As independent public accountants, we hereby consent to the incorporation by 
reference in this registration statement of our report dated February 9, 1998 
included in Nitinol Medical Technologies, Inc.'s Form 10-K for the year ended 
December 31, 1997 and to all references to our Firm included in this 
registration statement.



                                                  /s/ Arthur Andersen LLP
                                                  -----------------------
                                                  Arthur Andersen LLP



Boston, Massachusetts
November 11, 1998


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission